Efficacy and safety of FOLFIRINOX in elderly patients with advanced pancreatic adenocarcinoma.

被引：0
|
作者：
Jung, Jae Hyup
Kang, Jingu
Lee, Jong-Chan
Hwang, Jin-Hyeok
机构：
[1] Seoul Natl Univ, Bundang Hosp, Seongnam, South Korea
[2] Hallym Univ, Med Ctr, Dept Internal Med, Seoul, South Korea
[3] Seoul Natl Univ, Bundang Hosp, Dept Internal Med, Seongnam, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.e15729
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15729
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Modified FOLFIRINOX (mFOLFIRINOX) as second-line chemotherapy in pancreatic adenocarcinoma.
    Dean, Andrew Peter
    Higgs, Domenic
    James, Alex
    Van Gemert, Tegan
    James, Alena Talia
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [22] RAS mutations and their correlation with survival of patients with advanced pancreatic adenocarcinoma.
    Almeida, Thiago Lins
    Gomes, Jessica Ribeiro
    Cesar Machado, Marcel Cerqueira
    Buzaid, Antonio C.
    Maluf, Fernando C.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [23] Entinostat in combination with nivolumab for patients with advanced cholangiocarcinoma and pancreatic adenocarcinoma.
    Baretti, Marina
    Durham, Jennifer N.
    Walker, Rosalind
    Mitcheltree, Amber-Lynn
    Christmas, Brian
    Cope, Leslie
    Jaffee, Elizabeth M.
    Azad, Nilofer Saba
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [24] Circulating tumor DNA is prognostic and potentially predictive of eryaspase efficacy in patients with advanced pancreatic adenocarcinoma.
    Bachet, Jean-Baptiste
    Blons, Helene
    Hammel, Pascal
    El Hariry, Iman
    Portales, Fabienne
    Mineur, Laurent
    Metges, Jean-Philippe
    Mulot, Claire
    Bourreau, Camille
    Cain, Jason
    Cros, Jerome
    Laurent-Puig, Pierre
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [25] A triple approach strategy for patients with locally advanced pancreatic adenocarcinoma.
    Cantore, M.
    Girelli, R.
    Mambrini, A.
    Frigerio, I.
    Boz, G.
    Simoncini, E.
    Lusenti, A.
    Orlandi, M.
    Bassi, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [26] Safety and efficacy of modified FOLFIRINOX in patients with metastatic pancreatic cancer
    Watanabe, Kazuo
    Takahashi, Hideaki
    Umemoto, Kumiko
    Okuyama, Hiroyuki
    Hashimoto, Yusuke
    Ohno, Izumi
    Shimizu, Satoshi
    Mitsunaga, Shuichi
    Okusaka, Takuji
    Ikeda, Masafumi
    ANNALS OF ONCOLOGY, 2015, 26 : 88 - 88
  • [27] Efficacy and tolerability of tremelimumab in patients with metastatic pancreatic ductal adenocarcinoma.
    Sharma, Padmanee
    Dirix, Luc
    De Vos, Filip Yves Francine Leon
    Allison, James Patrick
    Decoster, Lore
    Zaucha, Renata
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [28] Gemcitabine/nabpaclitaxel in elderly patients with metastatic or locally advanced pancreatic adenocarcinoma: a retrospective analysis on the efficacy and safety profile
    Ventriglia, J.
    Laterza, M. M.
    Savastano, B.
    Petrillo, A.
    Tirino, G.
    Pompella, L.
    Pappalardo, A.
    Orditura, M.
    Ciardiello, F.
    De Vita, F.
    ANNALS OF ONCOLOGY, 2017, 28
  • [29] Gemcitabine/nabpaclitaxel efficacy in elderly patients with metastatic or locally advanced pancreatic adenocarcinoma
    Michalaki, V.
    Poydorou, A.
    Frangulidis, G.
    Vezakis, A.
    Karvouni, E.
    Papadimitriou, C.
    ANNALS OF ONCOLOGY, 2018, 29 : 44 - 44
  • [30] Folfirinox in elderly patients with pancreatic or colorectal cancer-tolerance and efficacy
    Jean-Florian Guion-Dusserre
    Aurélie Bertaut
    Fran?ois Ghiringhelli
    Julie Vincent
    Valérie Quipourt
    Sophie Marilier
    Zoé Tharin
    Leila Bengrine-Lefevre
    World Journal of Gastroenterology, 2016, (42) : 9378 - 9386
12345